No completed human efficacy or safety trial
S2CID 73781536
[4] Clinical practice typically involves reviewing medication history, assessing liver function, performing a full blood count, and considering haematological or hepatological referral when levels are markedly elevated without clear cause
In some cases, side effects are less about the peptide itself and more related to improper handling, overdosing, or contaminated sources from unverified suppliers
For those new to tirzepatide dosing in units , the escalation typically looks like this: 2.5mg for weeks 1-4, then 5mg for weeks 5-8, then 7.5mg for weeks 9-12, with optional increases to 10mg and 15mg for those who tolerate lower doses well but need additional appetite suppression
This finding is particularly significant given that some trials extended to 24 weeks of continuous exposure and included individuals with obesity-related health conditions who might have higher baseline health risks